GeneDx Holdings Corp. secured a new $100.0 million Term Loan Agreement with Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C. on February 27, 2026. The proceeds from the new Term Loan were primarily used to repay in full the company's existing term loan, dated October 27, 2023. Remaining funds are expected to be used for balance sheet optimization initiatives, including potential reductions of certain operating obligations, and for general corporate purposes. The Term Loan bears interest at a rate equal to Term SOFR plus a 4.50% margin, with a SOFR floor of 1.50%. The loan will mature and the principal amount must be repaid five years from the Closing Date, which is February 27, 2026. The obligations under the Loan Agreement are guaranteed by the Company's subsidiaries and secured by a first lien security interest in substantially all assets of the Company and Guarantors. The Loan Agreement includes a minimum liquidity covenant requiring the Company to maintain $50 million.